Definition

Chemistry, Manufacturing and Controls—CMC—is the section of a regulatory drug application that tells the agency everything it needs to know about how the drug substance and drug product are made, tested, and controlled. It covers the composition and structure of the molecule, the manufacturing process, analytical methods, specifications, stability data, and the overall quality control strategy. If the clinical sections of an application answer whether a drug works, CMC answers whether it can be made consistently and safely.

 

How CMC Requirements Evolve Across Development

CMC is not a fixed standard that applies equally at Phase 1 and commercial launch. It is phase-appropriate. Early on—at the pre-IND and Phase 1 stage—agencies want to see enough to be confident that the clinical supply is what it claims to be, free of significant safety risks, and manufactured with basic controls in place. Full analytical validation, formal process validation, and comprehensive stability packages are not expected at this stage.

As the programme advances through Phase 2 and Phase 3, expectations escalate substantially. Analytical methods must be validated. The impurity profile must be fully characterised and qualified against ICH Q3A thresholds. Process parameters must be defined and their acceptable ranges established. Stability data accumulates to support the intended shelf life. By the time an NDA or MAA is submitted, the CMC package represents years of accumulated technical documentation.

For programmes where a CDMO manufactures the drug substance, CMC is a shared responsibility. The CDMO holds the drug substance technical data in a Drug Master File; the sponsor integrates it into the broader application and ensures consistency between the DMF and their own CMC sections. Misalignment between these two documents is one of the most common causes of regulatory deficiency letters—and one of the most avoidable.

 

Related Topics

Related Topics

  • Drug Master File (DMF)
  • New Drug Application (NDA)
  • cGMP (Current Good Manufacturing Practice)
  • Impurity Profile of an API
  • Key Starting Material in API Synthesis
  • New Chemical Entity API (NCE API)

FAQs

  1. What does CMC cover in an IND submission?

    At the IND stage: identity and characterisation of the drug substance, a description of the manufacturing process, preliminary specifications and analytical methods, and the container-closure and storage conditions for the clinical supply. Formal validation is not yet required.

  1. How do CMC requirements change between Phase 1 and NDA?

    Phase 1 CMC is necessarily incomplete—it covers enough to demonstrate safety for initial dosing. By the NDA, the package must include validated analytical methods, a fully characterised and qualified impurity profile, process validation data, and stability data supporting the proposed shelf life and storage conditions.

  1. What connects a Drug Master File to a CMC submission?

    The DMF holds the drug substance manufacturing data in a confidential file with the agency. The sponsor references the DMF in their application and the DMF holder authorises the agency to review it as part of the overall submission.

  1. Who is responsible for CMC strategy when a CDMO is involved?

    The sponsor owns the submission strategy and is accountable to the agency. The CDMO owns the technical data for the drug substance. Clear contractual responsibility mapping—and regular technical alignment between both teams—is essential.

  1. What are the most common CMC deficiencies that delay approvals?

    Incomplete impurity qualification, insufficient process validation data, stability studies that do not support the requested shelf life, poorly defined critical process parameters, and inconsistencies between the DMF and the sponsor's CMC section.

 

Explore how Neuland's regulatory CMC expertise supports drug programmes from IND to commercial approval. Explore Custom Development